Featured

Status

Health Topics

Any Category
Diseases
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Clear Filters

Search Clinical Trials

80 Results
Completed
Fetal Hemoglobin Induction Treatment Metformin
This is a dose escalation, pilot study for subjects with sickle cell anemia (SCA) disease to determine if metformin has a beneficial effect on the treatment and quality of life …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Dental Malocclusion and Craniofacial Development in OI
Investigators will look at dental health in people with OI and will describe teeth misalignment and head and neck defects in individuals with moderate to severe Osteogenesis Imperfecta (OI). Investigators …
Baylor Role: Lead Sponsor
Recruiting
Investigation of the Genetics of Hematologic Diseases
Participants will be individuals (proband) receiving therapy or expert consultation regarding a non-malignant hematologic disorder. We propose to use genomics, transcriptomics, proteomics and metabolomic analysis coupled with family linkage studies …
Baylor Role: Collaborator
Terminated
Treatment of Adult Patients With Hemoglobin SC Disease (SCYTHE)
Patients will be recruited from the patient population followed at the Texas Children's Cancer and Hematology Centers (TCC/HC)/Baylor College of Medicine (BCM) and the University of Texas Houston Hematology Center. …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Urinary Biomarkers of OI Pathobiology
Osteogenesis Imperfecta (OI) is a rare disorder that causes bones to break easily. People with OI may have broken bones with little or no trauma, dentinogenesis imperfecta (DI), and, in …
Baylor Role: Lead Sponsor
Recruiting
BBD Longitudinal Study of Osteogenesis Imperfecta
The purpose of this natural history study is to perform a long-term follow-up of a large group of people with osteogenesis imperfecta (OI). The research aims are: 1. To collect …
Baylor Role: Lead Sponsor
Completed
Genomic Sequencing for Childhood Risk and Newborn Illness
The objective of this research protocol is to conduct a randomized clinical trial to assess the benefits and risks of adding the information from a genomic sequencing report to physician-mediated …
Baylor Role: Collaborator
Terminated
Treatment of Hemoglobin SC Disease With Hydroxyurea
To be eligible to participate in this study, patients must have HbSC disease, have experienced a sickle cell disease related complication, or have a score of 80 or lower on …
Baylor Role: Lead Sponsor
Completed
Comparative Efficacy of Phenylbutyrate (PBA) vs. Benzoate in Urea Cycle Disorders
The investigators will study and compare how effectively sodium phenylbutyrate, sodium benzoate, and a combination of the two, help excrete nitrogen in healthy volunteers. Subject participation will require three, separate, …
Baylor Role: Lead Sponsor
Completed
Nitric Oxide Supplementation in Argininosuccinic Aciduria
The investigators will perform a double blind, randomized, placebo-controlled, crossover study of NO supplementation in ASA patients assessing endothelial function and blood pressure as primary endpoints, and markers of nitric …
Baylor Role: Lead Sponsor